Aspect Analytics raises €10 million Series A to expand global leadership in spatial biology software

September 10, 2025 - Genk (BE)

Aspect Analytics, a leading provider of software for spatial biology data analysis, announced the successful closing of an oversubscribed € 10 million Series A funding round. The investment will accelerate the company’s international expansion, support continued innovation, and reinforce its position as the leader in spatial multi-omic data integration and large-scale research collaborations.

The announcement coincides with a strategic leadership transition. Marc Claesen, co-founder and former CEO, will assume the role of Chief Technology Officer, leveraging his deep expertise in spatial biology, machine learning, and artificial intelligence to drive the company’s AI-powered analytical capabilities. Steven Verhoeven will take on the role of Chief Executive Officer, bringing extensive experience in scaling VC- and PE-backed life sciences and diagnostics companies globally.

A unique approach to spatial biology

Aspect Analytics provides a patented software platform that enables researchers to integrate data from multiple spatial technologies, delivering true multi-omics insights. The Weave platform is uniquely capable of analyzing data at scale and deciphering complex multicellular environments, providing pharmaceutical and academic researchers with critical insights to uncover novel targets, unravel drug mechanisms of action, and optimize clinical trial cohorts.

Spatial biology is generating massive amounts of data but turning it into actionable insights is where the true value lies. Our high-end data analysis services and Weave platform remove critical barriers in spatial biology data analysis, management and visualization. This enables researchers to collaboratively integrate and interact with diverse datasets, analyze multicellular systems at scale, and leverage advanced AI/ML methods to uncover insights that were previously out of reach.

Marc Claesen, CTO Aspect Analytics

Fueling growth and global expansion

The Series A funding will support Aspect Analytics’ international expansion, continued product innovation, and delivery of unique, industry-leading capabilities to its customers. The round was led by PMV and Capricorn Partners, through their Capricorn Healthtech Fund II, alongside existing shareholders & management. Existing investors include Heran Partners, Gemma Frisius Fund and KU Leuven.

As we enter this next chapter, our goal is simple: scaling Aspect Analytics’ impact in drug discovery,” said Steven Verhoeven, CEO of Aspect Analytics. “With this investment, Marc driving our technology, and our team’s expertise, we’re ready to expand globally, empower researchers to unlock breakthrough discoveries, and set the standard in spatial biology data analysis.

Steven Verhoeven, CEO Aspect Analytics

2025 09 01 2025 09 01 Aspect Analytics 2 Movito 039 lr

Marc Claesen (CTO) - Nico Verbeeck (COO) - Steven Verhoeven (CEO)

Full press release (ENG-NL)

Press Release Series A Aspect Analytics ENG NL

About the companies

PMV (Participatie Maatschappij Vlaanderen)

The Flemish investment company PMV is shaping the future of the Flemish economy. PMV finances promising companies from the very start, through to growth and internationalization. PMV offers tailor-made financial solutions to entrepreneurs with a good business plan and a strong management team. It does so with capital, loans and guarantees. It also realizes, with and for the government, and other partners, projects that are important for prosperity and well-being in Flanders. PMV has a portfolio with 1.9 billion euros under management.

Capricorn Partners

Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as a competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is managing the venture capital funds Capricorn Chemistry Fund, Capricorn Digital Growth Fund, Capricorn ICT Arkiv, Capricorn Healthtech Fund, Capricorn Healthtech Fund II, Capricorn Industrial Biotech Fund and Capricorn Fusion China Fund. In addition it is the management company of Quest for Growth, quoted on Euronext Brussels, and the investment manager of Quest Cleantech Fund which is registered in Luxembourg.

Gemma Frisius Fund

The Gemma Frisius Fund (GFF) is a seed capital fund established in 1997 as a joint venture between KU Leuven, KBC Private Equity, and BNP Paribas Fortis Private Equity. It combines the university's expertise in research and technology transfer with the financial and investment knowledge of both financial partners. GFF provides start-up capital in the early development stages of innovative, research-oriented spin-off companies in all technological fields and guides them through their growth process.

Fill in your contactinformation to download the whitepaper